Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Kurne, D. Guc, H. Canpınar, Ö. Aydın, G. Sayat, M. Yörübulut, G. Esendagli, R. Karabudak (2011)
Analysis of BAFF and TRAIL expression levels in multiple sclerosis patients: evaluation of expression under immunomodulatory therapyActa Neurologica Scandinavica, 123
M. Buttmann, Cornelia Merzyn, H. Hofstetter, P. Rieckmann (2007)
TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-β treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic responseJournal of Neuroimmunology, 190
K. Wosik, K. Biernacki, Marie-Pierre Khouzam, A. Prat (2007)
Death receptor expression and function at the human blood brain barrierJournal of the Neurological Sciences, 259
M. Chawla-Sarkar, D. Leaman, E. Borden (2001)
Preferential Induction of Apoptosis by Interferon (IFN)-β Compared with IFN-α2Clinical Cancer Research, 7
C. Polman, S. Reingold, G. Edan, M. Filippi, H. Hartung, L. Kappos, F. Lublin, L. Metz, H. McFarland, P. O'Connor, M. Sandberg-wollheim, A. Thompson, B. Weinshenker, J. Wolinsky (2005)
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Annals of Neurology, 58
A. Hajifathali, A. Sayad, A. Sayad, A. Sayad, Z. Arjang, Y. Mohseni, Golamreza Babamohammadi, S. Zare, Ali Sarzaeem, A. Akbari, Nooshin Asgari (2012)
The association of -308 TNFα polymorphism and multiple sclerosis in Iranian patientsJournal of Biology and Today`s World, 1
B. Hilliard, A. Wilmen, C. Seidel, T. Liu, R. Göke, Youhai Chen (2001)
Roles of TNF-Related Apoptosis-Inducing Ligand in Experimental Autoimmune Encephalomyelitis1The Journal of Immunology, 166
J. Lünemann, S. Waiczies, S. Ehrlich, U. Wendling, Bibiane Seeger, T. Kamradt, F. Zipp (2002)
Death Ligand TRAIL Induces No Apoptosis but Inhibits Activation of Human (Auto)antigen-Specific T Cells1The Journal of Immunology, 168
Alastair Compston (1988)
The 150th anniversary of the first depiction of the lesions of multiple sclerosis.Journal of Neurology, Neurosurgery & Psychiatry, 51
M. Eftekharian, Mehrnoush Mousavi, Mona Hormoz, G. Roshanaei, M. Mazdeh (2014)
Multiple sclerosis and immunological-related risk factors: results from a case-control study.Human antibodies, 23 1-2
Christina Falschlehner, Uta Schaefer, H. Walczak (2009)
Following TRAIL’s path in the immune systemImmunology, 127
Chawla-Sarkar (2001)
Preferential induction of apoptosis by interferon (IFN)-compared with IFN-2: correlation with TRAIL/Apo2L induction in melanoma cell linesClin Canc Res, 7
E. Cretney, J. McQualter, N. Kayagaki, H. Yagita, C. Bernard, I. Grewal, A. Ashkenazi, M. Smyth (2005)
TNF‐related apoptosis‐inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in miceImmunology and Cell Biology, 83
M. Khademi, E. Wallström, M. Andersson, F. Piehl, R. Marco, T. Olsson (2000)
Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosisJournal of Neuroimmunology, 103
S. Rinta, H. Kuusisto, Minna Raunio, R. Paalavuo, Mari Levula, T. Lehtimäki, I. Elovaara (2008)
Apoptosis-related molecules in blood in multiple sclerosisJournal of Neuroimmunology, 205
M. Tawdy, M. Nasser, S. Shafy, M. Nada, M. Sirafy, A. Magd (2014)
Role of serum TRAIL level and TRAIL apoptosis gene expression in multiple sclerosis and relation to brain atrophyJournal of Clinical Neuroscience, 21
Hajifathali (2012)
The association of -308 TNFα polymorphism and multiple sclerosis in Iranian patientsCNB Journals, 1
A. Sayad, A. Allameh, A. Sayad, M. Noruzinia, M. Akbari, Ali Sarzaeem, A. Akbar, Reza Hoseini (2013)
The Association of -475 and -631 Interleukin-2 Gene Polymorphism with Multiple Sclerosis in Iranian PatientsCell Journal (Yakhteh), 15
M. Eftekharian, M. Ghannad, M. Taheri, G. Roshanaei, M. Mazdeh, M. Musavi, Mona Hormoz (2016)
Frequency of viral infections and environmental factors in multiple sclerosis.Human antibodies, 24 1-2
C. Polman, S. Reingold, B. Banwell, M. Clanet, Jeffrey Cohen, M. Filippi, K. Fujihara, E. Havrdová, M. Hutchinson, L. Kappos, F. Lublin, X. Montalban, P. O'Connor, M. Sandberg-wollheim, A. Thompson, E. Waubant, B. Weinshenker, J. Wolinsky (2011)
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 69
K. Wandinger, J. Lünemann, O. Wengert, J. Bellmann-Strobl, O. Aktas, A. Weber, E. Grundström, S. Ehrlich, K. Wernecke, H. Volk, F. Zipp (2003)
TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosisThe Lancet, 361
Compston (2008)
Multiple sclerosisLancet, 372
A. Sayad, A. Allameh, M. Noruzinia (2013)
THE INFLUENCE OF -330 IL-2 GENE POLYMORPHISM ON RELAPSING REMITTING AND SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IN IRANIAN PATIENTS, 18
F. Gilli, F. Marnetto, M. Caldano, A. Sala, S. Malucchi, M. Capobianco, A. Bertolotto (2006)
Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1Multiple Sclerosis, 12
M. Smyth, K. Takeda, Y. Hayakawa, J. Peschon, M. Brink, H. Yagita (2003)
Nature's TRAIL--on a path to cancer immunotherapy.Immunity, 18 1
R. Rudick, R. Ransohoff, R. Peppler, S. Medendorp, P. Lehmann, J. Alam (1996)
Interferon beta induces interleukin‐10 expression: Relevance to multiple sclerosisAnnals of Neurology, 40
A. Sayad (2014)
The association of −330 interleukin‐2 gene polymorphism and HLA‐DR15 allele in Iranian patients with multiple sclerosisInternational Journal of Immunogenetics, 41
BACKGROUND: Multiple sclerosis (MS) as an autoimmune disorder inwhich the insulating covers of neurons in the Central Nervous System aredestructed. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)is an immunomodulatory molecule to protect against T cells hyper activation.METHODS: In this Case-control study, we compare TRAIL geneexpression in peripheral blood between 50 relapse remitting MS patients and50 healthy controls by TaqMan Real time PCR. All the patients were negativefor HLA-DRB1*15 susceptible allele, normal serum vitamin D, responder toInterferon beta. All the health individuals were matched to patients. Also,we tried to find correlation between TRAIL gene expression and clinicalcharacteristics of patients.RESULTS: No statistically significantdifference was found in TRAIL mRNA expression between MS patients andcontrols (p> 0.05). There was no correlation in the TRAIL expression and ageof onset, disease duration and Expanded Disability Status Scale of Kurtzke(EDSS). As IFN-b may have stimulatory effects on immunoregulatory functionof TRAIL and all of our patients were treated with interferon beta and wereresponder, it lead to no significant change in TRAIL expression. We suggestcomparing between responders and non-responders should be investigated.
Human Antibodies – IOS Press
Published: Jan 1, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.